210 related articles for article (PubMed ID: 34410219)
1. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort.
Teira R; Diaz-Cuervo H; Aragão F; Muñoz J; Galindo P; Merino M; de la Fuente B; Sepúlveda MA; Domingo P; García J; Castaño M; Ribera E; Geijo P; Romero A; Peraire J; Deig E; Roca B; Martínez E; Estrada V; Montero M; Berenguer J; Espinosa N
HIV Res Clin Pract; 2021 Jun; 22(3):78-85. PubMed ID: 34410219
[No Abstract] [Full Text] [Related]
2. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
[TBL] [Abstract][Full Text] [Related]
3. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter?
Vergori A; Gagliardini R; Gianotti N; Gori A; Lichtner M; Saracino A; De Vito A; Cascio A; Di Biagio A; Monforte AD; Antinori A; Cozzi-Lepri A;
Int J Antimicrob Agents; 2020 Dec; 56(6):106154. PubMed ID: 32919008
[TBL] [Abstract][Full Text] [Related]
4. Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
Surial B; Ledergerber B; Calmy A; Cavassini M; Günthard HF; Kovari H; Stöckle M; Bernasconi E; Schmid P; Fux CA; Furrer H; Rauch A; Wandeler G;
J Infect Dis; 2020 Jul; 222(4):637-645. PubMed ID: 32189003
[TBL] [Abstract][Full Text] [Related]
5. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.
Hikasa S; Shimabukuro S; Hideta K; Higasa S; Sawada A; Tokugawa T; Tanaka K; Yanai M; Kimura T
J Infect Chemother; 2022 Mar; 28(3):396-400. PubMed ID: 34896027
[TBL] [Abstract][Full Text] [Related]
6. Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
Abe K; Obara T; Kamio S; Kondo A; Imamura J; Goto T; Ito T; Sato H; Takahashi N
AIDS Res Ther; 2021 Dec; 18(1):94. PubMed ID: 34876151
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
Surial B; Béguelin C; Chave JP; Stöckle M; Boillat-Blanco N; Doco-Lecompte T; Bernasconi E; Fehr J; Günthard HF; Schmid P; Walti LN; Furrer H; Rauch A; Wandeler G;
J Acquir Immune Defic Syndr; 2020 Oct; 85(2):227-232. PubMed ID: 32925387
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial.
Post FA; Yazdanpanah Y; Schembri G; Lazzarin A; Reynes J; Maggiolo F; Yan M; Abram ME; Tran-Muchowski C; Cheng A; Rhee MS
HIV Clin Trials; 2017 May; 18(3):135-140. PubMed ID: 28303753
[TBL] [Abstract][Full Text] [Related]
9. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
10. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization.
Brunet L; Mallon P; Fusco JS; Wohlfeiler MB; Prajapati G; Beyer A; Fusco GP
Clin Drug Investig; 2021 Nov; 41(11):955-965. PubMed ID: 34546533
[TBL] [Abstract][Full Text] [Related]
11. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
[TBL] [Abstract][Full Text] [Related]
12. Estimated glomerular filtration rate slopes on tenofovir alafenamide.
Ibrahim F; Campbell L; Bailey AC; Stockwell S; Waters L; Orkin C; Johnson M; Gompels M; De Burgh-Thomas A; Jones R; Schembri G; Mallon PW; Post FA
HIV Med; 2020 Oct; 21(9):607-612. PubMed ID: 33021067
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
Mills A; Crofoot G; McDonald C; Shalit P; Flamm JA; Gathe J; Scribner A; Shamblaw D; Saag M; Cao H; Martin H; Das M; Thomas A; Liu HC; Yan M; Callebaut C; Custodio J; Cheng A; McCallister S
J Acquir Immune Defic Syndr; 2015 Aug; 69(4):439-45. PubMed ID: 25867913
[TBL] [Abstract][Full Text] [Related]
14. Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients.
Seo JW; Kim K; Jun KI; Kang CK; Moon SM; Song KH; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Choe PG; Park WB; Oh MD
Infect Chemother; 2020 Sep; 52(3):381-388. PubMed ID: 32757496
[TBL] [Abstract][Full Text] [Related]
15. Recovery of renal function after early versus late switching of tenofovir disoproxil fumarate in people living with HIV with renal insufficiency.
Suppadungsuk S; Janepiriyaprayoon P; Sungkanuparph S
Int J STD AIDS; 2022 Mar; 33(4):391-396. PubMed ID: 35143730
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.
Tabak F; Zerdali E; Altuntaş O; Gunduz A; Bolukcu S; Mete B; Nakir IY; Kumbasar Karaosmanoglu H; Yildiz DS; Meric Koc M; Dokmetas İ;
Int J STD AIDS; 2021 May; 32(6):562-569. PubMed ID: 33599173
[TBL] [Abstract][Full Text] [Related]
17. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
Plum PE; Maes N; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Paquot N; Fombellida K; Vaira D; Moutschen M; Darcis G
BMC Infect Dis; 2021 Sep; 21(1):910. PubMed ID: 34488664
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study.
Su PY; Su WW; Hsu YC; Huang SP; Yen HH
PeerJ; 2021; 9():e12527. PubMed ID: 34820208
[TBL] [Abstract][Full Text] [Related]
19. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
[TBL] [Abstract][Full Text] [Related]
20. Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
Hermansson L; Yilmaz A; Price RW; Nilsson S; McCallister S; Makadzange T; Das M; Zetterberg H; Blennow K; Gisslen M
PLoS One; 2019; 14(12):e0226276. PubMed ID: 31826005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
